Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
July 10 2023 - 8:30AM
Nexalin Technology, Inc. (the “Company” or
“Nexalin”)
(Nasdaq: NXL; NXLIW) today announced
that Company’s abstract, titled: “MEG Source Imaging Reveals
Neuronal Changes in Combat-Related Mild Traumatic Brain Injury
after Transcranial Electrical Stimulation using Nexalin,” has been
accepted for a poster presentation at the upcoming 2023 Military
Health System Research Symposium (MHSRS) being held on August
14-17, 2023 at the Gaylord Palms Resort and Convention Center,
Kissimmee, Florida, USA.
The abstract was accepted under the breakout
session: Mental Health and Traumatic Brain Injury. The poster for
this breakout session will be presented in Poster Session 2 on
Tuesday, August 15, 2023. The poster will be available on the MHSRS
website after the meeting.
Mild traumatic brain injury (mTBI) is a leading
cause of sustained physical, cognitive, emotional, and behavioral
deficits in veterans and the general public. According to Global
Market Insights, the Traumatic Brain Injuries Assessment Market
size was valued at approximately $3.3 billion in 2022 and is
projected to reach over $7.2 billion in 2032.
The abstract describes the study using
Magnetoencephalography (MEG) to assess the neuronal changes in
veterans with combat-related mTBI after treatment delivered by
Nexalin’s non-invasive, frequency-based, deep-brain stimulation
device. The reduction of hyperactivity of delta- and gamma-band
activities in mTBI suggests the Nexalin treatment can reduce
deafferentation and GABA-ergic inhibitory interneuron dysfunctions
in chronic mTBI. Moreover, none of the veterans reported adverse
effects. The data supports the Company’s strategy to offer military
and civilian physicians a new tool to effectively treat mTBI
without the use of medication, and without side effects or adverse
events.
A prior clinical study of adult patients with
chronic insomnia, evaluating Nexalin’s non-invasive,
frequency-based deep-brain stimulation device, was performed in the
Laboratory of Neuromodulation, Department of Neurology, Xuanwu
Hospital of Capital Medical University, Beijing, China, which
demonstrated statistically significant improvements among patients.
According to an article in Science Direct, sleep disturbance is
common following traumatic brain injury (TBI), affecting 30–70% of
individuals, many occurring after mild injuries.
The 8-week randomized, double-blind,
parallel-group, sham-controlled study evaluated 62 patients. The
results demonstrated that, compared with the sham group, the active
group using Nexalin’s non-invasive, frequency-based deep-brain
stimulation device had higher response rates based on the
Pittsburgh Sleep Quality Index (PSQI) score changes from baseline
to the end of the 4-week intervention and to the 4-week follow-up,
and a higher remission rate at the end of the 4-week intervention.
During the 8-week period, the patients who received the active
intervention using Nexalin’s device had lower insomnia severity,
shortened sleep onset latency (SOL), elevated total sleep time
(TST), improved sleep efficiency, and increased sleep quality. No
adverse events or serious adverse responses occurred during the
study.
Mark White, CEO of Nexalin Technology, stated,
"We are honored to announce the acceptance of our abstract
regarding our non-invasive, frequency-based, deep-brain stimulation
device for presentation at the highly prestigious Military Health
System Research Symposium. This abstract reinforces and further
validates the growing body of clinical evidence supporting
Nexalin's new advanced 15 mAmp waveform, which we believe can have
a significant impact on improving mental healthcare outcomes among
patients affected with mild traumatic brain injury. We look forward
to fully disclosing the data at this prestigious event. We also
view this event as an important venue to gain awareness and
strengthen our relationships with the government and military
around this breakthrough technology. Importantly, this latest study
builds on prior data in insomnia, which has shown a high
correlation with TBI, as well as other indications such as anxiety
and depression.”
About Nexalin Technology,
Inc.
Nexalin designs and develops innovative
neurostimulation products to uniquely and effectively help combat
the ongoing global mental health epidemic. All of Nexalin’s
products are non-invasive and undetectable to the human body and
were developed to provide relief to those afflicted with mental
health issues. Nexalin utilizes bioelectronic medical technology to
treat mental health issues. Nexalin believes its non-invasive,
frequency-based, deep-brain stimulation medical devices can
penetrate structures deep in the mid-brain that are associated with
mental health disorders. Nexalin believes the deeper penetrating
waveform in its next-generation devices will generate enhanced
patient response without any adverse side effects. The Nexalin
device was recently approved in China by the National Medical
Products Administration (NMPA) for the treatment of insomnia and
depression. Additional information about the Company is available
at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that
constitute "forward-looking statements," These statements relate to
future events or Nexalin’s future financial performance. Any
statements that refer to expectations, projections or other
characterizations of future events or circumstances or that are not
statements of historical fact (including without limitation
statements to the effect that Nexalin or its management “believes”,
“expects”, “anticipates”, “plans”, “intends” and similar
expressions) should be considered forward looking statements that
involve risks and uncertainties which could cause actual events or
Nexalin’s actual results to differ materially from those indicated
by the forward-looking statements. Forward-looking statements are
subject to numerous conditions, many of which are beyond the
control of the Company, including those set forth in the Risk
Factors section of the Company's Report on Form 10-K for the year
ended December 31, 2022 and other filings as filed with the
Securities and Exchange Commission. Copies of such filings are
available on the SEC's website, www.sec.gov. Such forward-looking
statements are made as of the date hereof and may become outdated
over time. Such forward-looking statements are made as of the date
hereof and may become outdated over time. The Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
Contact:Crescendo Communications, LLCTel: (212)
671-1020Email: NXL@crescendo-ir.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/627369eb-eab1-45b2-a8be-1da5e1c9dba6
Nexalin Technologies (NASDAQ:NXL)
Historical Stock Chart
From Apr 2024 to May 2024
Nexalin Technologies (NASDAQ:NXL)
Historical Stock Chart
From May 2023 to May 2024